S&P 500   3,853.07 (+0.03%)
DOW   31,176.01 (-0.04%)
QQQ   326.36 (+0.80%)
AAPL   136.87 (+3.67%)
MSFT   224.97 (+0.28%)
FB   272.87 (+2.02%)
GOOGL   1,884.15 (+0.22%)
AMZN   3,306.99 (+1.34%)
TSLA   844.99 (-0.64%)
NVDA   554.70 (+3.75%)
BABA   260.00 (-2.07%)
CGC   33.56 (-0.21%)
GE   11.07 (-2.81%)
MU   85.01 (+1.81%)
AMD   91.53 (+3.13%)
NIO   58.34 (+1.09%)
T   28.83 (-0.45%)
F   11.53 (+6.17%)
ACB   11.17 (-3.21%)
BA   207.41 (-1.91%)
DIS   171.28 (-1.36%)
NFLX   579.84 (-1.11%)
GILD   66.98 (-1.49%)
S&P 500   3,853.07 (+0.03%)
DOW   31,176.01 (-0.04%)
QQQ   326.36 (+0.80%)
AAPL   136.87 (+3.67%)
MSFT   224.97 (+0.28%)
FB   272.87 (+2.02%)
GOOGL   1,884.15 (+0.22%)
AMZN   3,306.99 (+1.34%)
TSLA   844.99 (-0.64%)
NVDA   554.70 (+3.75%)
BABA   260.00 (-2.07%)
CGC   33.56 (-0.21%)
GE   11.07 (-2.81%)
MU   85.01 (+1.81%)
AMD   91.53 (+3.13%)
NIO   58.34 (+1.09%)
T   28.83 (-0.45%)
F   11.53 (+6.17%)
ACB   11.17 (-3.21%)
BA   207.41 (-1.91%)
DIS   171.28 (-1.36%)
NFLX   579.84 (-1.11%)
GILD   66.98 (-1.49%)
S&P 500   3,853.07 (+0.03%)
DOW   31,176.01 (-0.04%)
QQQ   326.36 (+0.80%)
AAPL   136.87 (+3.67%)
MSFT   224.97 (+0.28%)
FB   272.87 (+2.02%)
GOOGL   1,884.15 (+0.22%)
AMZN   3,306.99 (+1.34%)
TSLA   844.99 (-0.64%)
NVDA   554.70 (+3.75%)
BABA   260.00 (-2.07%)
CGC   33.56 (-0.21%)
GE   11.07 (-2.81%)
MU   85.01 (+1.81%)
AMD   91.53 (+3.13%)
NIO   58.34 (+1.09%)
T   28.83 (-0.45%)
F   11.53 (+6.17%)
ACB   11.17 (-3.21%)
BA   207.41 (-1.91%)
DIS   171.28 (-1.36%)
NFLX   579.84 (-1.11%)
GILD   66.98 (-1.49%)
S&P 500   3,853.07 (+0.03%)
DOW   31,176.01 (-0.04%)
QQQ   326.36 (+0.80%)
AAPL   136.87 (+3.67%)
MSFT   224.97 (+0.28%)
FB   272.87 (+2.02%)
GOOGL   1,884.15 (+0.22%)
AMZN   3,306.99 (+1.34%)
TSLA   844.99 (-0.64%)
NVDA   554.70 (+3.75%)
BABA   260.00 (-2.07%)
CGC   33.56 (-0.21%)
GE   11.07 (-2.81%)
MU   85.01 (+1.81%)
AMD   91.53 (+3.13%)
NIO   58.34 (+1.09%)
T   28.83 (-0.45%)
F   11.53 (+6.17%)
ACB   11.17 (-3.21%)
BA   207.41 (-1.91%)
DIS   171.28 (-1.36%)
NFLX   579.84 (-1.11%)
GILD   66.98 (-1.49%)
Log in
LON:NIPT

Premaitha Health PLC (NIPT.L) Share Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
9.10
MA: GBX 9.10
9.10
52-Week Range N/A
Volume1.57 million shs
Average Volume1.35 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Premaitha Health PLC, a molecular diagnostic company, develops tests for non-invasive prenatal screening and other applications in the United Kingdom and internationally. The company develops the IONA Test, an in vitro diagnostic non-invasive pre-natal screening test for pregnant women to estimate Down's syndrome, Edward's syndrome, and Patau's syndrome. The IONA test is a diagnostic system that enables clinical laboratory customers to perform the test in their own facilities. The company is headquartered in Manchester, the United Kingdom.
Premaitha Health PLC (NIPT.L) logo

MarketRank

Overall MarketRank

0.48 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-161-6676865
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive NIPT News and Ratings via Email

Sign-up to receive the latest news and ratings for NIPT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Premaitha Health PLC (NIPT.L) (LON:NIPT) Frequently Asked Questions

What stocks does MarketBeat like better than Premaitha Health PLC (NIPT.L)?

Wall Street analysts have given Premaitha Health PLC (NIPT.L) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Premaitha Health PLC (NIPT.L) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Premaitha Health PLC (NIPT.L)'s earnings last quarter?

Premaitha Health PLC (NIPT.L) (LON:NIPT) posted its quarterly earnings data on Friday, December, 29th. The company reported ($2.00) earnings per share (EPS) for the quarter. The business earned $2.71 million during the quarter.
View Premaitha Health PLC (NIPT.L)'s earnings history
.

Who are some of Premaitha Health PLC (NIPT.L)'s key competitors?

What other stocks do shareholders of Premaitha Health PLC (NIPT.L) own?

Who are Premaitha Health PLC (NIPT.L)'s key executives?

Premaitha Health PLC (NIPT.L)'s management team includes the following people:
  • Dr. Stephen Little, Exec. Vice Chairman (Age 61)
  • Mr. Barry Hextall, CFO, Sec. & Exec. Director
  • Mr. Peter Collins, Chief Bus. Officer & Exec. Director (Age 59)
  • Mr. Lyn Fafydd Rees, CEO & Director (Age 45)
  • Dr. Chia-Han Chan, Chief Scientific Officer & Director (Age 42)

What is Premaitha Health PLC (NIPT.L)'s stock symbol?

Premaitha Health PLC (NIPT.L) trades on the London Stock Exchange (LON) under the ticker symbol "NIPT."

How do I buy shares of Premaitha Health PLC (NIPT.L)?

Shares of NIPT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Premaitha Health PLC (NIPT.L)'s official website?

The official website for Premaitha Health PLC (NIPT.L) is www.premaitha.com.

How can I contact Premaitha Health PLC (NIPT.L)?

Premaitha Health PLC (NIPT.L)'s mailing address is Rutherford House, 40 Pencroft Way, MANCHESTER, M15 6SZ, United Kingdom. The company can be reached via phone at +44-161-6676865.

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.